At IMCAS World Congress 2025, the 8th edition of the Innovation Tank was held as part of a broader summit focused on the business of medical aesthetics. This unique program brought together leading professionals — from physicians and entrepreneurs to executives and investors — to explore the evolving structure, trends, and breakthroughs shaping dermatology, plastic surgery, aesthetics, and cosmeceuticals.
The Innovation Tank provided a global platform for start-ups to pitch their cutting-edge solutions before a high-profile jury and international audience. Each participant highlighted how their innovation addresses real-world clinical or market needs. One standout company earned the coveted Innovation of the Year title, while several others impressed both the jury and the audience with their visionary concepts.
Meet the 2025 winner and runner-ups whose innovations are redefining the landscape of aesthetic medicine.
🥇 SquareMind — Winner of the “Innovation of the Year” Award
SquareMind is on a mission to revolutionize skin examinations by making them faster, more efficient, and universally accessible. Its breakthrough innovation, Swan, is the world’s first robotic solution for full-body dermoscopy, launching in 2025. Swan performs automated, high-resolution skin scans in minutes. Its AI companion detects new or evolving pigmented lesions, helping physicians focus their expertise where it's needed most. By streamlining exams, Swan aims to redefine the standard of care in dermatology.
IMCAS spoke with Mr. Ali Khachlouf, CEO of SquareMind, about his experience.
How would you describe the experience of showcasing your innovation on the IMCAS stage?
“It was intense but a great exercise. In just five minutes, you need to clearly convey your company’s ‘why,’ what you’ve built, and where you stand — to a diverse audience unfamiliar with you or your problem. Keeping the story simple and engaging is key.”
What advice would you give to future startups aiming to take the stage?
“As Pasteur said, fortune favors the prepared mind. Preparation is everything, especially when pitching alongside other strong projects. Timing matters too — not too early when things are premature, and not too late either. Ideally, you want something tangible to show and a story that resonates.”
🥈 Raziel Therapeutics — Runner-up
Raziel Therapeutics is a phase-3-ready pharmaceutical company developing RZL-012, a novel injectable New Chemical Entity (NCE) for focal fat reduction. Targeting aesthetic indications like submental fat (“double chin”) and body contouring, RZL-012 offers a promising non-surgical approach to fat reduction.
🥉 Sylke — Runner-up
SYLKE® is a first-of-its-kind wound closure and dressing device made from 99.9999% silk fibroin — a biocompatible, non-immunogenic protein. Offering a water-resistant, long-lasting, and skin-friendly alternative to traditional synthetic devices, SYLKE® is the only FDA-registered silk-based wound closure solution. It reimagines silk, one of the oldest biomaterials in medicine, to advance healing without compromise.
Dr. Mark Mofid, President and CEO of Sylke, shared his reflections with IMCAS.
How would you describe the experience of presenting at IMCAS?
“We found it surprisingly non-intimidating, despite the expert panel of judges. Many audience members were industry or medical experts — and several have since approached me at other events to say they enjoyed hearing about our product.”
How did you prepare, and what would you recommend to future presenters?
“We prepared by presenting our financial data in a clear, visual format and anticipated tough questions in advance — much like a Shark Tank-style pitch.”
Tagged: 未来技术
Share this article on
